A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain

被引:80
作者
Kehl, LJ
Hamamoto, DT
Wacnik, PW
Croft, DL
Norsted, BD
Wilcox, GL
Simone, DA
机构
[1] Univ Minnesota, Sch Dent, Dept Oral Sci, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Sch Dent, Dept Diagnost & Surg Sci, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Sch Dent, Dept Pharmacol, Minneapolis, MN 55455 USA
[4] Univ Minnesota, Sch Dent, Dept Neurosci, Minneapolis, MN 55455 USA
[5] Univ Minnesota, Sch Dent, Dept Psychiat, Minneapolis, MN 55455 USA
关键词
hyperalgesia; carrageenan inflammation; bone cancer; cannabinoid receptors; WIN 55,212-2; grip force;
D O I
10.1016/S0304-3959(02)00450-5
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Pain associated with cancer and chronic musculoskeletal disorders can be difficult to control. We used murine models of cancer and inflammatory muscle pain to examine whether the cannabinoid receptor agonist WIN55,212-2 reduces hyperalgesia originating in deep tissues. C3H/He mice were anesthetized and implanted with osteolytic NCTC clone 2472 cells into the humeri or injected with 4% carrageenan into the triceps muscles of both forelimbs. At the time of peak hyperalgesia, WIN55,212-2 (1-30 mg/kg) or vehicle was administered intraperitoneally and forelimb grip force was measured 0.5-24 h later. WIN55,212-2 produced time- and dose-related antihyperalgesia in both models. A 10 mg/kg dose of WIN55,212-2 fully reversed carrageenan-evoked muscle hyperalgesia. However, 30 mg/kg of WIN55,212-2 attenuated tumor-evoked hyperalgesia only similar to50%. After controlling for the difference in magnitude of hyperalgesia between the two models, WIN55,212-2 was still more potent at reducing hyperalgesia in the inflammatory model. In the cancer pain model, the antihyperalgesic effect of WIN55,212-2 was partially blocked by pretreatment with the selective CB1 (SR141716A) but not the CB2 (SR144528) receptor antagonist. In contrast, both antagonists blocked antihyperalgesic effects of WIN55,212-2 on carrageenan-evoked muscle hyperalgesia. Catalepsy and loss of motor coordination, known side effects of cannabinoids, did not account for the antihyperalgesia produced by WIN55,212-2. These data show that cannabinoids attenuate deep tissue hyperalgesia produced by both cancer and inflammatory conditions. Interestingly, cannabinoids differentially modulated carrageenan- and tumor-evoked hyperalgesia in terms of potency and receptor subtypes involved suggesting that differences in underlying mechanisms may exist between these two models of deep tissue pain. (C) 2003 International Association for the Study of Pain. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:175 / 186
页数:12
相关论文
共 96 条
[1]   TREATMENT OUTCOME IN A MULTIDISCIPLINARY CANCER PAIN CLINIC [J].
BANNING, A ;
SJOGREN, P ;
HENRIKSEN, H .
PAIN, 1991, 47 (02) :129-134
[2]   PAIN, OPIOID USE, AND SURVIVAL IN HOSPITALIZED-PATIENTS WITH ADVANCED CANCER [J].
BRESCIA, FJ ;
PORTENOY, RK ;
RYAN, M ;
KRASNOFF, L ;
GRAY, G .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) :149-155
[3]   A PROSPECTIVE MULTICENTER ASSESSMENT OF THE EDMONTON STAGING SYSTEM FOR CANCER PAIN [J].
BRUERA, E ;
SCHOELLER, T ;
WENK, R ;
MACEACHERN, T ;
MARCELINO, S ;
HANSON, J ;
SUAREZALMAZOR, M .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1995, 10 (05) :348-355
[4]   Functional interactions between tumor and peripheral nerve: Changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain [J].
Cain, DM ;
Wacnik, PW ;
Turner, M ;
Wendelschafer-Crabb, G ;
Kennedy, WR ;
Wilcox, GL ;
Simone, DA .
JOURNAL OF NEUROSCIENCE, 2001, 21 (23) :9367-9376
[5]   Control of pain initiation by endogenous cannabinoids [J].
Calignano, A ;
La Rana, G ;
Giuffrida, A ;
Piomelli, D .
NATURE, 1998, 394 (6690) :277-281
[6]  
Carver AC, 2000, CANC MED, P2204
[7]   Cancer pain management [J].
Chang, HM .
MEDICAL CLINICS OF NORTH AMERICA, 1999, 83 (03) :711-+
[8]   The management of cancer pain [J].
Cherny, NI .
CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (02) :70-116
[9]  
Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159
[10]  
Cichewicz DL, 1999, J PHARMACOL EXP THER, V289, P859